期刊文献+

大三阳和小三阳患者自身抗体的检测结果分析

Analysis of the detection results of autoantibodies in patients with dasanyang and xiaosanyang
暂未订购
导出
摘要 目的分析比较大三阳和小三阳慢性乙型肝炎患者的自身抗体的检测结果。方法2016年5月至2018年4月,根据430例慢性乙型肝炎患者的乙肝两对半检测结果,将其分为大三阳和小三阳两组。采集患者清晨空腹静脉血4ml,分离血清后,对自身抗体加以检测,检测内容包括ANA、SMA、LC-1、AMA、LKM、SLA和ENA等。结果大三阳组患者ANA、AMA、LKM和LC-1的阳性率分别为90.23%、88.72%、51.13%和81.95%,小三阳组患者以上4项自身抗体的阳性率分别为51.18%、46.80%、18.52%和44.78%。大三阳组ANA等4项自身抗体的阳性率均高于小三阳组,两组比较差异均有统计学意义(P<0.05)。结论大三阳慢性乙型肝炎患者ANA、AMA、LKM和LC-1的阳性率高于小三阳组。 Objective To analyze and compare the detection results of autoantibodies in patients with chronic hepatitis b in dasanyang and xiaosanyang. Methods From May 2016 to April 2018, 430 patients with chronic hepatitis b were divided into two groups according to the HBV two-half test results. 4ml of the patients' fasting venous blood was collected in the morning. After the serum was separated, the autoantibodies were tested, including ANA, SMA, lc-1, AMA, LKM, SLA and ENA, etc. Results The positive rates of ANA, AMA, LKM and lc-1 in the three positive groups were 90.23%, 88.72%, 51.13% and 81.95%, respectively. The positive rates of the above four autoantibodies in the three positive groups were 51.18%, 46.80%, 18.52% and 44.78%, respectively. The positive rate of ANA and other four autoantibodies in the big three positive group was higher than that in the small three positive group, and the difference between the two groups was statistically significant (P<0.05). Conclusion The positive rates of ANA, AMA, LKM and lc-1 in patients with chronic hepatitis b were higher than those in patients with minor hepatitis b.
作者 李清元 李振燕 滕彦玲 Li Qingyuan;Li Zhenyan;Teng Yanling(Department Of Clinical Laboratory, Jilin Central Hospital, Jilin, Jilin, 132011, China)
出处 《当代医学》 2019年第16期78-79,共2页 Contemporary Medicine
关键词 慢性乙型肝炎 大三阳 小三阳 自身抗体 Chronic hepatitis b Big three positive Small three positive Autoantibodies
  • 相关文献

参考文献10

二级参考文献85

  • 1张艳,陆志檬,王耆煌,林晓红,崔大敷.丙型肝炎病毒感染相关自身抗体(抗-GOR)的测定及其临床意义[J].上海免疫学杂志,1993,13(5):287-290. 被引量:2
  • 2李桂珍,刘兴祥,王兴亮.江苏地区不同类型乙型肝炎患者HBV基因分型研究[J].第四军医大学学报,2007,28(2):157-159. 被引量:15
  • 3Cacoub P,Saadoun D,Bourlière M,et al.Hepatitis B virus genotypes and extrahepatic manifestations.J Hepatol,2005,43(5):764-770.
  • 4Turkbey B,Ocak I,Daryanani K,et al.Autosomal receagive polycystic kidney disease and congenital hepatic fibrosis (ARPKD/CHF).Pediatr Radio,2009,39(2):100-111.
  • 5Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy[J]. Gastroenterology, 2003, 124(1): 105-117. DOl: http://dx.doi.orglIO.l053/gast.2003.50013.
  • 6Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease[J]. N Engl J Med, 2004, 3SI(1S): IS21-IS31. DOl: IO.lOS6INEJMoa033364.
  • 7European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1): 167-185. DOl: 10.10161 j.jhep.2012.02.01O.
  • 8Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update[J]. Clin Gastroenterol Hepatol, 2008, 6(12): 131S- 1341; quiz 1286. DOl: IO.lOI6/j.cgh.2008.08.021.
  • 9Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C[J]. Hepatology, 2011, 54(5): 1591-1599. DOl: 10.l002lhep.24555.
  • 10Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B[J]. Hepatology, 2008, 47(2): 428-434. DOl: 10.1 002Ihep.22065.

共引文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部